Last reviewed · How we verify
Ketamine low-dose
At a glance
| Generic name | Ketamine low-dose |
|---|---|
| Sponsor | Cedars-Sinai Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Awareness Neuraxial Versus General Anesthesia in Frail Patients Undergoing Laparoscopic or Robotic Abdominopelvic Surgery. (NA)
- Ketamine for Multiple Sclerosis Fatigue (PHASE2)
- Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT) (PHASE3)
- Ketamine for Opioid Use Disorder (PHASE2)
- Ketamine Low dOse Evaluation on Morphine Consumption in Traumatic Patient (PHASE3)
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or Behavior (PHASE2)
- Intraoperative Multimodal Monitoring as a Means in Reducing the Duration of Mechanical Ventilation in High-Risk Patients Undergoing Major Abdominal Procedures - A Pilot Study (NA)
- Comparison of Intravenous Ondansetron and Low Dose Ketamine in Preventing Post Spinal Shivering (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ketamine low-dose CI brief — competitive landscape report
- Ketamine low-dose updates RSS · CI watch RSS
- Cedars-Sinai Medical Center portfolio CI